Rethinking Trial Design With Bayesian Approaches

Traditional clinical trials typically rely on “frequentist” statistical methods, which analyze results only after the study is completed. Bayesian approaches offer a different framework that updates the probability of a treatment’s effectiveness as new data becomes available during the trial.

In part 3 of this Applied Clinical Trials interview, biostatistics expert David Morton discusses how growing regulatory support—particularly from the FDA—is encouraging broader adoption of Bayesian methods in clinical trial design.